NEC OncoImmunity AS  news

April 8, 2022; OSLO, Norway/ TOKYO, Japan: CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under its US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronavir

• VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field
• NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022

Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC Co

The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI.

NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing approach from the blood of numerous donors using deep targeted HLA sequencing. The validation con

• TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4).
• TG4050 monotherapy was also associated with the first signs of clinical activity.

TG4050 was well tolerated, with no related Serious Adverse Events reported across the two studies to date.

Additional patients are being enrolled, with the aim to treat up to 43 patients across the

NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will develop a novel T-cell diagnostic for the current COVID-19 pandemic to complement the current serologic

Oslo, April 22, 2020 – NEC OncoImmunity AS today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19 and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europ

OncoImmunity AS today announced that it has been acquired by NEC Corporation, the renowned Japanese IT and network company, that recently launched its Artificial Intelligence (AI) driven drug discovery business. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.

OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients. 

OncoImmunity announced today the signing of a collaboration agreement with a T cell therapy company based in the US . The companies will cooperate to access the predictive capabilities of OncoImmunity`s artificial intelligence platform called the Immuneoprofiler™ to identify immunogenic neoantigens for the US partner’s T-cell platform.